Clinical Trials in Essential Thrombocythemia (ET)
PharmaEssentia is committed to advancing the treatment of Essential Thrombocythemia (ET) through rigorous clinical research. The company is currently enrolling participants for two significant trials:
-
A Phase 3 Trial: This open-label, multicenter, randomized, active-controlled trial evaluates the efficacy, safety, tolerability, and pharmacokinetics of ropeginterferon alfa-2b-njft after 12 months of treatment compared with anagrelide (ANA) as second-line therapy for adult patients with ET who have shown resistance or intolerance to hydroxyurea (HU). The trial is registered under ClinicalTrials.gov: NCT04285086.
-
A Phase 2b Trial: This single-arm, multicenter trial assesses the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adult patients with ET in the US and Canada. The trial is registered under ClinicalTrials.gov: NCT05482971.
For more information about these trials, interested parties can contact the study information center at 1-800-999-2449 or email the PharmaEssentia Medical Information team at medinfo@pharmaessentia-us.com.